GlassScriptPhysician profile
Alexa J Limes
NPI 1689199077
$2,734.93
in general payments reported to CMS, 2019-2025
23 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.39 · 2022: $69.33 · 2023: $248 · 2024: $556 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,414.45 |
| Education | $197.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $403.08 | 2024-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $342.33 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $313.25 | 2025 | |
| Lilly USA, LLC | $282.99 | 2024-2025 | Olumiant, Taltz, Ebglyss |
| Janssen Pharmaceuticals, INC | $233.39 | 2023 | Xarelto |
| Genzyme Corporation | $207.20 | 2024-2025 | |
| Incyte Corporation | $133.09 | 2024-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $127.80 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $124.77 | 2024 | Fasenra |
| Sanofi-Aventis U.S. LLC | $86.99 | 2025 | |
| Galderma Laboratories, L.P. | $83.92 | 2025 | Nemluvio |
| Pfizer INC. | $79.77 | 2024-2025 | |
| Shionogi INC | $69.33 | 2022 | |
| Leo Pharma INC. | $45.68 | 2025 | Anzupgo, Adbry |
| Depuy Synthes Sales INC. | $37.16 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $28.64 | 2025 | |
| Ucb, INC. | $28.07 | 2024 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.91 | 2024 | Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $20.63 | 2025 | Sotyktu |
| Biofrontera INC. | $18.58 | 2025 | |
| Smith+Nephew, INC. | $16.23 | 2021 | |
| Bioventus LLC | $14.21 | 2023 | Durolane |
| Organon LLC | $12.91 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexa Limes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.